Stockreport

Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP [Yahoo! Finance]

Immunovant, Inc.  (IMVT) 
PDF underway; the program targets an orphan-size, treatment-naïve disease with no FDA-approved therapies and will use refined endpoints (IGA 0/1 with two-point reduction) af [Read more]